<DOC>
	<DOC>NCT00326625</DOC>
	<brief_summary>Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under the skin, for the treatment of ALS. The study drug is a higher dose formulation of CopaxoneÂ® (20 mg/ml GA), a marketed medication, approved for the treatment of relapsing-remitting multiple sclerosis. GA is an immunomodulating drug that has anti inflammatory and neuroprotective properties, which are believed to be of therapeutic value in ALS. The study treatment duration is 1 year (52 weeks).</brief_summary>
	<brief_title>Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>1. Diagnosis of definite or probable ALS in accordance with the ElEscorial criteria. 2. Subject has experienced his/her first ALS symptoms within 3 years prior to the screening visit. 3. Slow VC test equal or greater than 70% of the predicted value. 4. The sum of the 3 respiratory items on the ALSFRSR must total at least 10 points. 5. Stable dose of riluzole for at least 8 weeks prior to screening. 6. Age 1870 (inclusive). 1. The use of invasive or noninvasive ventilation. 2. Subject having undergone gastrostomy. 3. Subject with any clinically significant or unstable medical condition. 4. Subjects participating in any other clinical trial (within 12 weeks prior to screening and thereafter). 5. Additional criteria per protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>